Volume 29, Issue 2 (June 2025)                   Physiol Pharmacol 2025, 29(2): 135-145 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hamzanloui Moghadam K, Alazzawi W, Derakhshan S, Karimi A, Shahsavari Z, Goudarzi A. Expression of Apolipoprotein C-I (Apo C-I) in oral squamous cell carcinoma. Physiol Pharmacol 2025; 29 (2) :135-145
URL: http://ppj.phypha.ir/article-1-2383-en.html
Expression of Apolipoprotein C-I (Apo C-I) in oral squamous cell carcinoma
Kurosh Hamzanloui Moghadam , Walla Alazzawi , Samira Derakhshan , Abbas Karimi , Zahra Shahsavari , Afsaneh Goudarzi
Abstract:   (1182 Views)

Introduction: One of the most common cancers of the oral cavity is oral squamous cell carcinoma (OSCC). Previous studies have provided evidence that apolipoprotein C-I (Apo C-I) has an oncogenic role beyond its classical function. Although it has been investigated in prostate, breast, and lung cancer, there is no information available regarding Apo C-I expression in tumor and pri-tumor tissues of OSCC patients. Thus, the goal of the present study was to unravel the expression of Apo C-I in OSCC and investigate its correlation with the survival and grade of OSCC patients.
Methods: The Apo C-I mRNA level was measured in tumor and pri-tumor tissues of 16 OSCC patients. In addition, the 34 paraffin-embedded tissues of OSCC patients and IHC technique were used to analyze the association of Apo C-I protein with the survival of OSCC patients. 
Results: The mRNA (P=0.0386) gene expression of Apo C-I showed a statistically significant difference between tumor and pri-tumor tissues of OSCC patients. It seems that a high protein level of Apo C-I is related with poor survival of OSCC patients (P=0.04). The Apo C-I protein was positively correlated with the tumor site (Pearson r= 0.485, P=0.0036) but not the grade (Pearson r= 0.2295, P=0.1917). Our data showed that high Apo C-I protein levels might be correlated with poor survival of OSCC patients.
Conclusion: Our findings suggest that patients with high protein levels of Apo C-I may have lower survival, making it a potential prognostic factor for OSCC. However, further investigation is necessary to establish this concept.

Keywords: Apolipoprotein C-I, Oral Squamous Cell Carcinoma, Survival
Full-Text [PDF 807 kb]   (81 Downloads)    
Type of Manuscript: Experimental research article | Subject: Cell, Stem Cell and Cancer
References
1. Argiris A, Karamouzis M V, Raben D, Ferris R L. Head and neck cancer. The Lancet 2008; 371: 1695-1709. [DOI:10.1016/S0140-6736(08)60728-X]
2. Cui Y, Miao C, Hou C, Wang Z, Liu B. Apolipoprotein C1 (APOC1): A novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma. Front Oncol 2020; 10: 1436. [DOI:10.3389/fonc.2020.01436]
3. Dominiczak M H. Risk factors for coronary disease: the time for a paradigm shift? Clin Chem Lab Med 2001; 39: 907-919. [DOI:10.1515/CCLM.2001.147]
4. Durrington P. Dyslipidaemia. Lancet 2003; 362: 717-731. [DOI:10.1016/S0140-6736(03)14234-1]
5. Feller L, Lemmer J. Oral squamous cell carcinoma: Epidemiology, clinical presentation and treatment. Journal of Cancer Therapy 2012; 03: 263-268. [DOI:10.4236/jct.2012.34037]
6. Gharat S A, Momin M, Bhavsar C. Oral Squamous Cell Carcinoma: Current treatment strategies and nanotechnology-based approaches for prevention and therapy. Crit Rev Ther Drug Carrier Syst 2016; 33: 363-400. [DOI:10.1615/CritRevTherDrugCarrierSyst.2016016272]
7. Halliday D, Venkatesan S, Pacy P. Apolipoprotein metabolism: a stable-isotope approach. Am J Clin Nutr 1993; 57: 726S-730S; discussion 730S-731S. [DOI:10.1093/ajcn/57.5.726S]
8. Huang Y, Zhang X, Jiang W, Wang Y, Jin H, Liu X, et al. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique. Eur J Obstet Gynecol Reprod Biol 2012; 165: 96-103. [DOI:10.1016/j.ejogrb.2012.06.031]
9. Jiang H, Tang J-Y, Xue D, Chen Y-M, Wu T-C, Zhuang Q-F, et al. Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling. Cancer Cell International 2021; 21: 41. [DOI:10.1186/s12935-020-01713-x]
10. Klee E W, Bondar O P, Goodmanson M K, Dyer R B, Erdogan S, Bergstralh E J, et al. Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clin Chem 2012; 58: 599-609. [DOI:10.1373/clinchem.2011.171637]
11. Ko H L, Wang Y S, Fong W L, Chi M S, Chi K H, Kao S J. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase I trial. Thorac Cancer 2014; 5: 500-508. [DOI:10.1111/1759-7714.12117]
12. Lee G, Jeong Y S, Kim D W, Kwak M J, Koh J, Joo E W, et al. Clinical significance of APOB inactivation in hepatocellular carcinoma. Exp Mol Med 2018; 50: 1-12. [DOI:10.1038/s12276-018-0174-2]
13. Li Q, Hu Y, Zhou X, Liu S, Han Q, Cheng L. Role of oral bacteria in the development of oral squamous cell carcinoma. Cancers (Basel) 2020a; 12. [DOI:10.3390/cancers12102797]
14. Li Y-l, Wu L-w, Zeng L-h, Zhang Z-y, Wang W, Zhang C, et al. ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3. Oncogene 2020b; 39: 6203-6217. [DOI:10.1038/s41388-020-01428-3]
15. Luo X L, Zhong G Z, Hu L Y, Chen J, Liang Y, Chen Q Y, et al. Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma. Oncotarget 2015; 6: 44037-44048. [DOI:10.18632/oncotarget.5823]
16. Mahley R W, Innerarity T L, Rall S C, Jr., Weisgraber K H. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277-1294. [DOI:10.1016/S0022-2275(20)34443-6]
17. Panarese I, Aquino G, Ronchi A, Longo F, Montella M, Cozzolino I, et al. Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Review of Anticancer Therapy 2019; 19: 105-119. [DOI:10.1080/14737140.2019.1561288]
18. Ren H, Chen Z, Yang L, Xiong W, Yang H, Xu K, et al. Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer. Cancer Management and Research 2019a; 11: 4917-4930. [DOI:10.2147/CMAR.S192529]
19. Ren L, Yi J, Li W, Zheng X, Liu J, Wang J, et al. Apolipoproteins and cancer. Cancer Medicine 2019b; 8: 7032-7043. [DOI:10.1002/cam4.2587]
20. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 1991; 266: 18259-18267. [DOI:10.1016/S0021-9258(18)55263-7]
21. Shi H, Huang H, Pu J, Shi D, Ning Y, Dong Y, et al. Decreased pretherapy serum apolipoprotein A-I is associated with extent of metastasis and poor prognosis of non-small-cell lung cancer. Onco Targets Ther 2018; 11: 6995-7003. [DOI:10.2147/OTT.S170227]
22. Su W P, Sun L N, Yang S L, Zhao H, Zeng T Y, Wu W Z, et al. Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro. J Biochem Mol Toxicol 2018; 32: e22158. [DOI:10.1002/jbt.22158]
23. Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F, et al. Apolipoprotein C-I maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene 2008; 27: 2810-2822. [DOI:10.1038/sj.onc.1210951]
24. Thomson P J, Potten C S, Appleton D R. Mapping dynamic epithelial cell proliferative activity within the oral cavity of man: a new insight into carcinogenesis? Br J Oral Maxillofac Surg 1999; 37: 377-383. [DOI:10.1054/bjom.1999.0130]
25. Xue A, Chang J W, Chung L, Samra J, Hugh T, Gill A, et al. Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma. Br J Cancer 2012; 107: 1883-1891. [DOI:10.1038/bjc.2012.458]
26. Yang Y, Zhao S, Fan Y, Zhao F, Liu Q, Hu W, et al. Detection and identification of potential biomarkers of non-small cell lung cancer. Technol Cancer Res Treat 2009; 8: 455-466. [DOI:10.1177/153303460900800607]
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.